Rheumatologist Receives Scleroderma Foundation's Lifetime Achievement Award PDF Print E-mail
Thursday, 17 September 2009 10:52
In a recent Medical News Today article, it was reported that Thomas A. Medsger Jr., M.D.,  Gerald P. Rodnan Professor of Medicine, University of Pittsburgh School of Medicine, received the Scleroderma Foundation's Lifetime Achievement Award in recognition of his service to the Scleroderma community. The award is the foundation's highest honor and is presented to individuals who have devoted a minimum of 20 years of service, either as a volunteer or professional, to the Scleroderma community.

Dr. Medsger has served as chief of the University of Pittsburgh's Division of Rheumatology and Clinical Immunology, and director of the Scleroderma Research Program and UPMC's Scleroderma Clinic. His primary clinical and investigative interest is in Scleroderma and other connective tissue diseases.

In 2001 and 2005, Dr. Medsger was the recipient of the Scleroderma Foundation's Doctor of the Year award. He also has been designated as one of the Best Doctors in America by American Health Magazine for the past two decades and was the recipient of the American College of Rheumatology's Distinguished Rheumatologist Award. Recently, he had the title of "Master" conferred upon him by the American College of Rheumatology - a title awarded to members of high professional competence, ethics and moral standing who have significantly furthered the science of rheumatology.

Dr. Medsger currently serves as the Scleroderma Foundation Western Pennsylvania Chapter's treasurer and interim president. He has written numerous articles for the Foundation's Voice magazine and has published more than 300 journal articles about scleroderma and related diseases.

Read the full article here.
 
More articles :

» Erectile Dysfunction Drug Could Improve Raynaud’s Symptoms Associated with Scleroderma

Adding tadalafil (Cialis®; Adcirca®) to the treatment of people with can improve ’s phenomenon symptoms and heal and prevent hand and finger associated with it, according to research presented this week at the American College of Rheumatology...

» Geneticists Hunt for Scleroderma Triggers

In all its forms, gives Dartmouth geneticist Michael Whitfield, his graduate students, and his postdoctoral researchers a sense of urgency in their search for the triggers of the chronic condition. In a study that the Journal of Investigative...

» Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?

Eric Hachulla, MD, PhD; David Launay, MD, PhD; Luc Mouthon, MD, PhD; Olivier Sitbon, MD, PhD; Alice Berezne, MD; Loïc Guillevin, MD; Pierre-Yves Hatron, MD; Ge´rald Simonneau, MD; Pierre Clerson, MD; and Marc Humbert, MD, PhD;Pulmonary arterial...

» Researchers Testing Intense Pulsed Light As An Alternative Treatment for Telangiectatases

Telangiectatases are knot-like clusters of blood vessels on the skin which can occur in 30 to 50 per cent of patients with Systemic Sclerosis, also known as . Telangiectases tend to occur on the face, neck, and upper limbs and can cause...

» Real-World Bosentan Therapy Successful in Pulmonary Arterial Hypertension: Presented at ATS

Real-life experiences in treating patients with pulmonary arterial hypertension with bosentan appears to provide similar efficacy as seen in clinical trials -- despite patients being somewhat older and having more scleroderma, researchers said today...

» Role of ACE Inhibitors in Preventing Scleroderma Renal Crisis Remains Unclear

Scleroderma patients on angiotensin-converting enzyme inhibitors at the onset of Scleroderma renal crisis do not appear to have worse outcomes than do those not taking the antihypertensive agents prior to the acute renal function deterioration,...